Evidence map›Paper›PMID 37904133›Full record

ArticleCell communication and signaling : CCS2023

Neutral sphingomyelinase inhibition promotes local and network degeneration in vitro and in vivo.

Michael L Risner, Marcio Ribeiro, Nolan R McGrady, Bhanu S Kagitapalli, Xitiz Chamling, Donald J Zack, David J Calkins

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Cell communication and signaling : CCS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. On the road: extracellular vesicles in intercellular communication.Cell communication and signaling : CCS · 2025
    Article
  13. Review
  14. Neutral sphingomyelinase 2: A promising drug target for CNS disease.Advances in pharmacology (San Diego, Calif.) · 2025
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Michael L RisnerDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, AA7103 MCN/VUIIS, 1161 21st Ave S., Nashville, TN, 37232, USA. MLRisner@Oakland.Edu.
Marcio RibeiroDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, AA7103 MCN/VUIIS, 1161 21st Ave S., Nashville, TN, 37232, USA.
Nolan R McGradyDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, AA7103 MCN/VUIIS, 1161 21st Ave S., Nashville, TN, 37232, USA.
Bhanu S KagitapalliDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, AA7103 MCN/VUIIS, 1161 21st Ave S., Nashville, TN, 37232, USA.
Xitiz ChamlingDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Donald J ZackDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
David J CalkinsDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, AA7103 MCN/VUIIS, 1161 21st Ave S., Nashville, TN, 37232, USA. David.J.Calkins@VUMC.org.
Vanderbilt University Medical Center · USJohns Hopkins Medicine · US

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
Retinal Ganglion Cell Replacement in Optic NeuropathiesU24EY029903 · NEI · STANFORD UNIVERSITY · PI CALKINS, DAVID J., GOLDBERG, JEFFREY L · 2018 to 2024
$7.5M
Developing Remyelination Strategies for Demyelinating Optic Neuropathies Using Human Pluripotent Stem CellsR00EY029011 · NEI · JOHNS HOPKINS UNIVERSITY · PI CHAMLING, XITIZ · 2022 to 2024
$731k
NEI NIH HHS P30 EY026877NEI NIH HHS R00 EY029011NEI NIH HHS R00EY029011NEI NIH HHS U24 EY029903NEI NIH HHS U24-EY029903
6 · The paper itself

Abstract

backgroundCell-to-cell communication is vital for tissues to respond, adapt, and thrive in the prevailing milieu. Several mechanisms mediate intercellular signaling, including tunneling nanotubes, gap junctions, and extracellular vesicles (EV). Depending on local and systemic conditions, EVs may contain cargoes that promote survival, neuroprotection, or pathology. Our understanding of pathologic intercellular signaling has been bolstered by disease models using neurons derived from human pluripotent stems cells (hPSC).

methodsHere, we used hPSC-derived retinal ganglion cells (hRGC) and the mouse visual system to investigate the influence of modulating EV generation on intercellular trafficking and cell survival. We probed the impact of EV modulation on cell survival by decreasing the catabolism of sphingomyelin into ceramide through inhibition of neutral sphingomyelinase (nSMase), using GW4869. We assayed for cell survival in vitro by probing for annexin A5, phosphatidylserine, viable mitochondria, and mitochondrial reactive oxygen species. In vivo, we performed intraocular injections of GW4869 and measured RGC and superior colliculus neuron density and RGC anterograde axon transport.

resultsFollowing twenty-four hours of dosing hRGCs with GW4869, we found that inhibition of nSMase decreased ceramide and enhanced GM1 ganglioside accumulation. This inhibition also reduced the density of small EVs, increased the density of large EVs, and enriched the pro-apoptotic protein, annexin A5. Reducing nSMase activity increased hRGC apoptosis initiation due to enhanced density and uptake of apoptotic particles, as identified by the annexin A5 binding phospholipid, phosphatidylserine. We assayed intercellular trafficking of mitochondria by developing a coculture system of GW4869-treated and naïve hRGCs. In treated cells, inhibition of nSMase reduced the number of viable mitochondria, while driving mitochondrial reactive oxygen species not only in treated, but also in naive hRGCs added in coculture. In mice, 20 days following a single intravitreal injection of GW4869, we found a significant loss of RGCs and their axonal recipient neurons in the superior colliculus. This followed a more dramatic reduction in anterograde RGC axon transport to the colliculus.

conclusionOverall, our data suggest that perturbing the physiologic catabolism of sphingomyelin by inhibiting nSMase reorganizes plasma membrane associated sphingolipids, alters the profile of neuron-generated EVs, and promotes neurodegeneration in vitro and in vivo by shifting the balance of pro-survival versus -degenerative EVs. Video Abstract.

Indexed as

Sphingomyelin PhosphodiesteraseSphingomyelinsAniline CompoundsAnimalsAnnexin A5Benzylidene CompoundsCell Membrane StructuresCeramidesHumansMiceNanotubesPhosphatidylserinesReactive Oxygen SpeciesRetinal Ganglion CellsAniline CompoundsAnnexin A5Benzylidene CompoundsCeramidesGW 4869PhosphatidylserinesReactive Oxygen SpeciesSphingomyelin PhosphodiesteraseSphingomyelinsTunneling NanotubesApoptosisCeramideExtracellular vesiclesGM1 gangliosideHuman embryonic stem cellsMitochondriaNeutral sphingomyelinaseRetinal ganglion cells

Identifiers

PMID37904133
PMCPMC10614343
OpenAlexW4388033337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.